Acquisition Announced

Eli Lilly and Company acquisition of AtaiBeckley

US$2.8bn equity value

Announced 16 Jul 2026 · NASDAQ: ATAI · US$6.75 cash and scrip per share · 40% premium

Advisers

Eli Lilly and Company

Acquirer

Financial adviser
Legal adviser
Target
AtaiBeckley
Acquirer
Eli Lilly and Company
Target based in
United States
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Drug Development, Behavioral Health

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.